Clinical trials: Stable Coronary Heart Disease
Drug-Eluting Stents, Percutaneous Coronary Intervention
Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation
This study is a prospective,multi-center, open-label, randomized controlled clinical trial,aims to assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in…
- Trial name
- NCT03008083
- Testing
- 3 months DAPT, 12 months DAPT
- Where
- China
- Volunteers
- 2,446 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Hypertension
Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers
A randomized, open-label, fed, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 in healthy volunteers
- Trial name
- NCT03748212
- Testing
- D935 Cap. 1T, CKD-385 Tab. 1T
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy
Use of Beta-agonists in Stable Severe Congestive Heart Failure
The purpose of this study is to determine whether Salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure
- Trial name
- NCT01447069
- Testing
- Salbutamol
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rabin Medical Center
Ischemic Heart Disease, Angina, Stable
Post-Revascularization Optimization and PHysiological Evaluation of intermediaTe Lesions
PROPHET-FFR is a single center ambispective registry aiming to explore the impact of post-revascularization functional assessment on later outcomes.
- Conditions
- Ischemic Heart Disease, Angina, Stable, Non ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction
- Trial name
- PROPHET-FFR (NCT05056662)
- Testing
- Invasive functional evaluation with either Pd/Pa, FFR, iFR or contrast FFR
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Catholic University of the Sacred Heart
Coronary Artery Disease, Dyslipidemia
The Impact of Tredaptive on Flow-Mediated Dilation in Cardiac Patients
Laropiprant (LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist.
- Trial name
- NCT01052311
- Testing
- Tredaptive (1 g extended release niacin+ 20 mg laropiprant), Tredaptive
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Sheba Medical Center
Chronic Coronary Syndrome
Optimal Evaluation to Reduce Cardiovascular Imaging Testing
In daily clinical routine, the evaluation of new-onset and stable chest pain (SCP) suggestive of chronic coronary syndrome (CCS) remains a challenge for physicians.
- Trial name
- OPERATE (NCT05640752)
- Testing
- 2019 ESC guideline-determined diagnostic strategy, 2016 NICE guideline-determined diagnostic strategy
- Where
- 4 sites in China
- Volunteers
- 800 people
- Sponsor
- Tianjin Chest Hospital
CAD, Stable Angina Pectoris
Percutaneous Coronary Angioplasty Compared With Exercise Training in Symptomatic Coronary Artery Disease
The purpose of this study is to compare coronary angioplasty with stent implantation with an exercise rehabilitation program in patients with stable coronary artery disease (CAD).
- Trial name
- NCT00176358
- Testing
- PTCA and Stent Implantation, Exercise Training
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- University of Leipzig
Stable Angina
Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy
Thanks to rapid reendothelialization derived from the pro-healing property of the EPC capture stent, 1-month dual antiplatelet therapy (DAPT) is recommended after EPC capture stent implantation.
- Trial name
- INNOVATION (NCT01394848)
- Testing
- Endothelial cell capture stent with 1 month clopidogrel, Everolimus eluting stent with 12 month clopidogrel, Atorvastatin 20mg loading
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Yonsei University
Stable Coronary Artery Disease
RBD1119 in Coronary Artery Disease (CAD)
CAD is driven by atherosclerosis in the coronary arteries and is a major cause of myocardial infarction, heart failure, arrhythmias, and premature death.
- Trial name
- NCT07884136
- Testing
- RBD1119
- Where
- 16 sites in Poland, Sweden
- Volunteers
- 200 people
- Sponsor
- Ribocure Pharmaceuticals AB
Stable Angina
Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases
Through the literature review , we pick out a series of forward-looking biological indicators as follows : 1. NGAL 2. Cystatin C: 3. Galectin-3: 4. Copeptin: 5. MR-Pro ANP: 6. sST2:
- Trial name
- NCT02179047
- Testing
- coronary angiography
- Where
- Taiwan
- Volunteers
- 214 people
- Sponsor
- Taipei City Hospital
Atherosclerosis
SB-480848 In Subjects With Coronary Heart Disease
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of…
- Trial name
- NCT00269048
- Testing
- SB-480848
- Where
- 119 sites in United States, Argentina and 14 more
- Volunteers
- 969 people
- Sponsor
- GlaxoSmithKline
Stable Angina, Unstable Angina
International Randomized Comparison Between DES Limus Carbostent and Taxus DES in the Treatment of De-novo Coronary Lesions
The purpose of this study is to demonstrate non-inferiority in terms of safety and efficacy of DES Limus Carbostent compared to the Taxus Liberté in treating de-novo atherosclerotic lesions in native coronary arteries.
- Conditions
- Stable Angina, Unstable Angina, Documented Silent Ischemia
- Trial name
- NEXT (NCT01373502)
- Testing
- DES Limus Carbostent, Taxus Liberté Stent
- Where
- 11 sites in Belgium, France and 2 more
- Volunteers
- 323 people
- Sponsor
- CID - Carbostent & Implantable Devices
Stable Angina, Unstable Angina, Silent Coronary Ischemia, Coronary Artery Disease
ISAR-DAPT (A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial)
This clinical trial studies patients treated with the Coroflex ISAR Stent for coronary artery disease in order for the objective of verifying the non-inferiority of results that among patients who were administered DAPT for 3…
- Trial name
- NCT02609698
- Testing
- Coroflex ISAR, 3 months DAPT, 6 months DAPT
- Where
- South Korea
- Volunteers
- 906 people
- Sponsor
- Ajou University School of Medicine
Angina (Stable), Coronary Artery Disease(CAD)
Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds
ORBITA-SOLAR is an invasive physiological cardiac catheterisation study that aims to determine whether different coronary stenoses have different angina thresholds.
- Conditions
- Angina (Stable), Coronary Artery Disease(CAD), Ischaemic Heart Disease (IHD)
- Trial name
- ORBITA-SOLAR (NCT07386418)
- Testing
- Percutaneous coronary intervention (PCI), Measurement of the angina threshold
- Where
- 7 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Chronic Coronary Syndrome, Coronary Artery Disease
Feasibility of a Deep Learning-based Algorithm for Non-invasive Assessment of Vulnerable Coronary Plaque
The primary objective of this study is to assess the accuracy in terms of sensitivity, specificity, negative and positive predicted values of the DL-based algorithm with respect to correct identification of the plaque and…
- Conditions
- Chronic Coronary Syndrome, Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- FOCUS DL (NCT06186336)
- Testing
- Deep Learning-based Vulnerable Plaque Detection and Assessment Tool
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- GE Healthcare
Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI)
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients.
- Conditions
- Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)
- Trial name
- NCT01020383
- Testing
- ALX-0081, ReoPro®
- Where
- 39 sites in Austria, Belgium and 5 more
- Volunteers
- 364 people
- Sponsor
- Ablynx, a Sanofi company
Heart Failure
Digoxin Withdrawal in Stable Heart Failure
Heart failure is a chronic condition in which the heart fails to function as a pump to move blood around the body. This sets up a complex physiologic response to compensate, which include activation of many hormonal mechanisms…
- Trial name
- NCT01398371
- Testing
- Withdrawal of digoxin, Digoxin
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- The Alfred
Coronary Artery Disease, Coronary Microvascular Dysfunction
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
The objective of this study is to investigate, as a proof-of-principle, long-term (52 weeks) effects of tirzepatide once-weekly vs.
- Conditions
- Coronary Artery Disease, Coronary Microvascular Dysfunction, Overweight or Obesity, Stable Angina Pectoris
- Trial name
- IDEAL-COR (NCT06606821)
- Testing
- Tirzepatide
- Where
- 3 sites in Denmark
- Volunteers
- 124 people
- Sponsor
- Tina Vilsbøll
Coronary Artery Disease
A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- NCT00528411
- Testing
- Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Valvular Heart Disease
Pre-habilitation of Patients Scheduled for Cardiac Valve Surgery
Cardiac rehabilitation (CR) is an integral part of cardiovascular disease management incorporating aspects of scientifically constructed appropriate physical exercise.
- Trial name
- NCT03571906
- Testing
- Tele - Cardiac Pre-Rehabilitation
- Volunteers
- 25 people
- Sponsor
- Sheba Medical Center